ReviewClinical rheumatology2013
Role of interleukin-10 and interleukin-10 receptor in systemic lupus erythematosus.
Review in Clinical rheumatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.
- Association between interleukin-10-819T/C polymorphism and risk of ischemic stroke: A meta-analysis.Medicine · 2020Pooled it
- Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus.Scientific reports · 2016Trial
- Protein biomarkers of inflammation in women with SLE and their newborn children.Lupus science & medicine · 2026Article
- The relationship between IL-10 levels, gene polymorphisms and histiocytic necrotizing lymphadenitis in children.BMC pediatrics · 2026Article
- IL-17ACR open rheumatology · 2025Article
- IL-10 in Systemic Lupus Erythematosus: Balancing Immunoregulation and Autoimmunity.International journal of molecular sciences · 2025Article
- Cytokines unveiled: their impact on oral and multisystem features of lupus erythematosus.Frontiers in immunology · 2025Review
- Methyl-donor supplementation in women with systemic lupus erythematosus with different nutritional status: the protocol for a randomised, double-blind, placebo-controlled trial.Lupus science & medicine · 2024Article
- Autoimmunity-Associated SNP rs3024505 Disrupts STAT3 Binding in B Cells, Leading to IL10 Dysregulation.International journal of molecular sciences · 2024Article
- Article
- IL-10 Neutralization Attenuates Mast Cell Responses in a Murine Model of Experimental Food Allergy.ImmunoHorizons · 2024Article
- Peripheral cytokine interleukin-10 alleviates perihematomal edema after intracerebral hemorrhage via interleukin-10 receptor/JAK1/STAT3 signaling.CNS neuroscience & therapeutics · 2024Article
- The Impact of the IL-10 Gene Polymorphism on mRNA Expression and IL-10 Serum Concentration in Polish Lupus Patients.International journal of molecular sciences · 2024Article
- IL-10 Differentially Promotes Mast Cell Responsiveness to IL-33, Resulting in Enhancement of Type 2 Inflammation and Suppression of Neutrophilia.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Association ofInternational journal of molecular sciences · 2023Article
- Vitamin D Presented In Vitro Immunomodulatory Property on T Lymphocyte-Related Cytokines in Systemic Lupus Erythematosus.Inflammation · 2023Article
- Downregulation of inflammatory erectile dysfunction byToxicology reports · 2023Article
- Under the influence: environmental factors as modulators of neuroinflammation through the IL-10/IL-10R axis.Frontiers in immunology · 2023Review
- Human umbilical cord mesenchymal stem cells derived extracellular vesicles regulate acquired immune response of lupus mouse in vitro.Scientific reports · 2022Article
- Parapoxvirus Interleukin-10 Homologues Vary in Their Receptor Binding, Anti-Inflammatory, and Stimulatory Activities.Pathogens (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by excessive production of a variety of autoantibodies, accumulation of immune complexes, and multiple organ systems involvement. Interleukin-10 (IL-10) has an important role in the growth, survival, differentiation, and function of B cells. Abnormally increased IL-10 synthesis seems contributing to the spontaneous hyperactivity of the B cell compartment, so that it can directly result in autoantibody production by committed plasma cells, circulating immune complexes formation, and eventually in tissue and organ damage, suggesting it might associate with the development of SLE. A better understanding of the regulation of IL-10 and its receptors (IL-10R) can likely provide more valuable clues to the pathogenic mechanisms underlying specific forms of SLE, so as to pave the way toward more effective therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.